Britain and America have hammered out a landmark bilateral deal that will guarantee no import taxes on British pharmaceutical products going into the US market.
The Terms of the Accord
In exchange for the tariff guarantee, the UK has agreed to increase funding on medicines through the public health system. This pledge secures that duties on these key goods will remain at zero for a timeframe of three years.
This development is in response to previous warnings to hike tariffs on patented pharmaceutical products, with figures discussed as high as double the cost.
"This agreement with the Britain strengthens the worldwide climate for new treatments and establishes much-needed equity to transatlantic drug exports," an announcement said.
Trade Importance
Medicines are one of the UK's biggest goods shipped to the America, which is by far the largest destination for major British pharmaceutical firms.
Export figures show that in the 12 months to the end of September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This guarantee secures employment, stimulates investment and paves the way for the UK to emerge as a global hub for biotech and pharma," a minister stated.
Specific UK Commitments
The agreement includes several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will raise the price threshold at which it deems new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a aim to raise total NHS spending on medicines from 0.3% of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The sum drug companies must refund to the NHS to control costs will be capped at fifteen percent. In the past, repayments exceeded 20%.
Industry Background
This agreement follows a ongoing tension between the pharmaceutical industry and the ministers over spending levels and NHS adoption.
The disagreement were exacerbated by assertions that US patients were paying several times more for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been halted or scrapped, while multi-billion-dollar investments have been announced toward projects in the United States.
A senior figure stated that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the past decade.
